It has been reported that IGF2BP1 may serve as a prognostic marker in melanoma, on account of IGF2BP1 being overexpressed in metastatic melanoma, which leads to resistance to chemotherapeutic agents (Craig and Spiegelman, 2012; Fortis et al., 2017). Here, IGF2BP1 is linked to melanoma.